C4 Therapeutics (CCCC) Non Operating Income (2019 - 2026)

C4 Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 6.54% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $10.2 million (down 24.23% YoY), while the FY2025 annual figure was $10.3 million, down 28.28% from the prior year.
• Non Operating Income for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Non Operating Income was $3.9 million in Q1 2024, with the low at -$251000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.5 million (2025), against an average of $2.2 million.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income soared 5978.57% in 2023, then plunged 37.23% in 2025.
• C4 Therapeutics' Non Operating Income stood at $1.1 million in 2022, then jumped by 166.25% to $2.9 million in 2023, then grew by 10.75% to $3.3 million in 2024, then slipped by 14.91% to $2.8 million in 2025, then declined by 4.46% to $2.7 million in 2026.
• Business Quant data shows CCCC's Non Operating Income at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.2 million in Q3 2025.